Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of the Immunomodulating Agent Belumosudil (KD025) After Combined Kidney and Hematopoeitic Stem Cell Transplantation to Induce Transplant Tolerance: A Pilot Study

NCT05806749 is registered in ClinicalTrials.gov with University of California, Los Angeles as lead sponsor.

NCT NCT05806749
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05806749 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of the Immunomodulating Agent Belumosudil (KD025) After Combined Kidney and Hematopoeitic Stem Cell Transplantation to Induce Transplant Tolerance: A Pilot Study
Lead sponsor
University of California, Los Angeles
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 7, 2023
Completion date
August 31, 2028
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney diseases, end stage kidney disease, immunological tolerance, kidney transplant failure and rejection